Business Wire·Jun 4, 2026, 7:00 AM ET

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

AN2 Therapeutics reported 100% elimination of Trypanosoma cruzi parasites in nonhuman primates after 28 days of AN2-502998 treatment with durable effects lasting four months post-treatment.
The Phase 1 First-In-Human study demonstrated a favorable safety profile for AN2-502998 with no dose-limiting toxicities observed at exposure levels consistent with nonhuman primate efficacy thresholds.
AN2-502998 is an oral CPSF3 inhibitor derived from a boron chemistry platform & is the first compound to show curative activity in nonhuman primates with naturally acquired chronic Chagas disease.
The treatment targets a global market of approximately 10 million people with chronic Chagas disease, including over 300,000 in the U.S., where no FDA-approved adult therapies currently exist.
Potential regulatory benefits include eligibility for an FDA Tropical Disease Priority Review Voucher upon approval due to the high unmet medical need for chronic Chagas disease treatments.
The company plans to initiate a Phase 2 proof-of-concept study late in 2026 in collaboration with the Drugs for Neglected Diseases initiative (DNDi).
AN2-502998 targets the same CPSF3 enzyme as acoziborole, which was recently approved by the EMA for human African trypanosomiasis.